Trifecta™ Long Term Follow-Up (LTFU) Study

Completed

Conditions: Aortic Valve Regurgitation
Aortic Valve Stenosis
Aortic Valve Insufficiency
Aortic Valve Incompetence

Interventions: Device: Trifecta™ Valve

Registration Number: NCT01593917

Lead Sponsor: Abbott Medical Devices

Brief Summary: The Trifecta™ LTFU Study is a single-arm, multi-center, prospective, non-randomized, post-market study conducted in the United States and Canada to collect long-term safety and effectiveness data through 10 years after implant of the Trifecta™ aortic bioprosthetic valve. The Trifecta™ is a tri-leaflet stented pericardial valve designed for supraannular placement in the aortic position. The Trifecta™ LTFU Study is an extension of the Trifecta™ Investigational Device Exemption (IDE) Study (NCT00475709) conducted to support United States Food and Drug Administration (FDA) approval of the Trifecta™ valve. All Trifecta™ LTFU Study subjects received Trifecta™ valve implants during participation in the Trifecta™ IDE study and subsequently consented to extended annual follow-up through 10 years under the Trifecta™ LTFU protocol.

Detailed Description: This clinical study was designed as an extension of the Trifecta™ IDE Study supporting FDA approval of the Trifecta™ valve. A total of 11 Trifecta™ IDE Study investigational sites in the United States (n=9) and Canada (n=2) participated in the Trifecta™ LTFU Study. Study enrollment included 329 subjects implanted from 2007 through 2009 at these 11 sites during the IDE Study who consented to participate in continued annual follow-up through 10 years post-implant. Of these 329 subjects, 140 also participated in the FDA-mandated Trifecta™ Post-Approval Study (PAS, NCT01514162) prior to consenting to additional annual follow-up under the Trifecta™ LTFU protocol. The remaining 189 subjects entered the Trifecta™ LTFU Study directly from the Trifecta™ IDE Study.

The Trifecta™ LTFU Study database subsumes all data collected in the 329 participants under the Trifecta™ IDE and Trifecta™ PAS protocols and extends these data through 10 years from each subject's original date of implant in the Trifecta™ IDE Study. The Trifecta™ LTFU Study data thus encompass 10 years of continuous annual post-implant follow-up in the 329 participants as well as their pre-implant Baseline Visit data. Data collected includes adverse events, assessments of heart failure symptoms by New York Heart Association (NYHA) functional classification, and echocardiographic assessments of Trifecta™ valve function.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 329

Inclusion Criteria

Patient currently has a Trifecta™ aortic valve that was implanted at one of the U.S. or Canadian investigational sites during the Trifecta™ IDE study.
Patient met eligibility criteria prior to enrollment in the Trifecta™ IDE study.
Patient agrees to complete all required follow-up visits.
Patient provided written informed consent prior to any study related procedure, as approved by the governing Institutional Review Board (IRB) or the Ethics Committee (EC) of the investigational site.

Exclusion Criteria

Patient is currently participating or planning to participate in any other study unless approved by the Sponsor.

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Subjects previously implanted with a Trifecta™ valve in the Trifecta™ IDE Study	Trifecta™ Valve	Subjects enrolled in this clinical study were implanted with the Trifecta™ aortic bioprosthetic valve during 2007, 2008 and 2009 as part of the Trifecta™ IDE Study conducted to obtain FDA approval.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Freedom From Reoperation for Structural Valve Deterioration at 10 Years Post-Implant	10 years post-implant	Percentage of participants free from surgical explant or valve-in-valve transcatheter aortic valve implantation for treatment of structural deterioration of the Trifecta™ valve through 10 years post-implant. This percentage is estimated from time-to-event data using the Kaplan-Meier estimator. Structural valve deterioration is deterioration intrinsic to the bioprosthetic valve, due to leaflet calcification, leaflet tears, or other causes, that results in prosthetic valve stenosis or regurgitation.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Freedom From All-Cause Mortality at 10 Years Post-Implant	10 years post-implant	Percentage of participants free of death from any cause through 10 years after implant with the Trifecta™ valve, estimated from time-to-event data using the Kaplan-Meier estimator.
Percentage of Participants With Freedom From Valve-Related Mortality at 10 Years Post-Implant	10 years post-implant	Percentage of participants free from death related to the Trifecta™ valve through 10 years after implant, estimated from time-to-event data using the Kaplan-Meier estimator. Valve-related mortality includes deaths due to any of the following events involving the study valve: structural valvular deterioration, nonstructural valve dysfunction, valve thrombosis, embolism, bleeding events, endocarditis, or reoperation. Sudden, unexplained deaths of participants implanted with the Trifecta™ valve are also counted as valve-related mortality.
Percentage of Participants With Freedom From Structural Valve Deterioration at 10 Years Post-Implant	10 years post-implant	Percentage of participants free of structural deterioration of the Trifecta valve through 10 years after implant, estimated from time-to-event data using the Kaplan-Meier estimator. Structural valve deterioration is deterioration intrinsic to the bioprosthetic valve, due to leaflet calcification, leaflet tears, or other causes, that results in prosthetic valve stenosis or regurgitation. The presence of structural valve deterioration is determined by direct visualization of the valve at explant or autopsy or by echocardiographic or other cardiac imaging criteria for assessment of valvular stenosis and regurgitation.

Trial Locations

Locations (11): Mission Health & Hospitals
🇺🇸
Asheville, North Carolina, United States
St. Paul's Hospital
🇨🇦
Vancouver, British Columbia, Canada
Hospital of the University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States
Institut de Cardiologie de Quebec (HÃ´pital Laval)
🇨🇦
Quebec, Canada
USC University Hospital
🇺🇸
Los Angeles, California, United States
Abbott Northwestern Hospital
🇺🇸
Minneapolis, Minnesota, United States
Vanderbilt University Medical Center
🇺🇸
Nashville, Tennessee, United States
The Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
Intermountain Salt Lake Cardiovascular and Thoracic Surgery
🇺🇸
Salt Lake City, Utah, United States
Main Line Health Center/Lankenau Hospital
🇺🇸
Wynnewood, Pennsylvania, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States